```html

Wegener’s Disease (Granulomatosis with Polyangiitis)

Overview

Granulomatosis with polyangiitis (GPA), historically known as Wegener’s granulomatosis, is a rare, systemic autoimmune vasculitis that primarily attacks small‑ and medium‑sized blood vessels. The inflammation can cause necrosis (tissue death) and granuloma formation in the respiratory tract, kidneys, and other organs.

• Incidence: Approximately 3 – 4 new cases per million people each year in the United States and Europe.<sup>[1] CDC</sup>
• Prevalence: About 30 – 50 cases per million population worldwide.<sup>[2] Mayo Clinic</sup>
• Age & gender: Most commonly diagnosed between ages 40–65, with a slight male predominance (≈1.2 : 1). However, children and older adults can be affected.

Because its symptoms mimic infections, malignancies, and other autoimmune diseases, early recognition is essential to prevent organ damage.

Symptoms

Symptoms vary depending on which organs are involved, but the classic triad involves the upper airway, lower airway, and kidneys. Below is a comprehensive list with brief descriptions.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, facial pain, or post‑nasal drip.
• Nasal crusting or ulceration – may lead to perforation of the nasal septum.
• Ear problems – otitis media, hearing loss, or vertigo.
• Eye involvement – scleritis, episcleritis, or conjunctival redness.

Lower Respiratory Tract

• Cough – dry or productive.
• Hemoptysis – coughing up blood, ranging from streaks to large amounts.
• Shortness of breath – especially on exertion.
• Chest pain – pleuritic (sharp, worsens with breathing).

Kidneys (Renal)

• Hematuria – blood in the urine, often “cola‑colored.”
• Proteinuria – foamy urine, indicating protein loss.
• Decreased urine output – may progress to renal failure if untreated.

Systemic / Other Organ Involvement

• Fever, fatigue, weight loss – common but non‑specific.
• Skin lesions – palpable purpura, livedo reticularis, or ulcerations.
• Joint pain – arthralgia without swelling.
• Peripheral neuropathy – tingling or numbness.
• Gastrointestinal symptoms – abdominal pain, bleeding, or perforation (rare).
• Cardiac involvement – pericarditis, myocarditis, or coronary vasculitis.

Causes and Risk Factors

The exact trigger for GPA remains unknown, but research points to a combination of genetic predisposition and environmental factors that provoke an abnormal immune response.

Immunologic Mechanism

• ANCA antibodies – Most patients have anti‑proteinase‑3 (PR3‑ANCA, formerly c‑ANCA). These auto‑antibodies activate neutrophils, causing them to adhere to vessel walls and release inflammatory enzymes.

Genetic Factors

• Certain HLA‑DQ alleles (e.g., HLA‑DQβ1*04) increase susceptibility.<sup>[3] NIH</sup>

Environmental Triggers

• Silica dust exposure – occupational exposure (mining, construction) has been linked to higher ANCA‑associated vasculitis risk.
• Infections – Staphylococcus aureus colonization of the nose is more common in GPA and may act as a trigger or perpetuator.
• Medications – Rarely, drugs such as propylthiouracil or cocaine adulterated with levamisole can induce ANCA‑positive vasculitis.

Who Is at Higher Risk?

• Adults aged 40–65 (peak incidence).
• Men slightly more than women.
• People with a family history of autoimmune disease.
• Individuals with occupational silica exposure.

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and tissue biopsy. No single test is definitive.

Laboratory Tests

• ANCA testing – PR3‑ANCA (c‑ANCA) is positive in 70‑90% of generalized disease; MPO‑ANCA (p‑ANCA) may be present in limited forms.
• Complete blood count (CBC) – often shows anemia of chronic disease.
• Renal function panel – serum creatinine, blood urea nitrogen (BUN) to assess kidney involvement.
• Urinalysis – hematuria, red blood cell casts, proteinuria.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging

• Chest X‑ray – may reveal nodules, cavitary lesions, or infiltrates.
• High‑resolution CT (HRCT) of the chest – better delineates nodules, ground‑glass opacities, and sinus disease.
• Sinus CT – shows mucosal thickening, bone destruction, or nasal septal perforation.

Biopsy (Gold Standard)

• Respiratory tract biopsy – granulomatous inflammation with necrotizing vasculitis.
• Kidney biopsy – crescentic glomerulonephritis, a hallmark of severe disease.

Classification Criteria

The 2022 ACR/EULAR classification criteria combine clinical features, ANCA status, and histopathology to standardize diagnosis for research and clinical practice.<sup>[4] ACR/EULAR</sup>

Treatment Options

Therapy aims to induce remission quickly, then maintain it with lower‑intensity medication to minimize toxicity. Treatment is individualized based on disease severity (limited vs. generalized) and organ involvement.

Induction Therapy (Remission‑Inducing)

• High‑dose glucocorticoids – Prednisone 1 mg/kg/day (max 60 mg) orally or IV methylprednisolone pulses (500–1000 mg/day for 3 days) for severe disease.
• Cyclophosphamide – Oral (2 mg/kg/day) or IV (15 mg/kg every 2‑3 weeks) for 3–6 months; most effective for renal or pulmonary life‑threatening disease.
• Rituximab – Anti‑CD20 monoclonal antibody, 375 mg/m² weekly × 4 weeks or 1 g on days 1 and 15; comparable efficacy to cyclophosphamide with less gonadal toxicity.<sup>[5] NEJM</sup>
• Plasma exchange (PLEX) – Considered for severe renal failure (creatinine >5 mg/dL) or diffuse alveolar hemorrhage; recent PEXIVAS trial suggests limited mortality benefit but may be used selectively.<sup>[6] JAMA</sup>

Maintenance Therapy (Prevent Relapse)

• Azathioprine – 2 mg/kg/day for 12‑24 months.
• Mycophenolate mofetil (MMF) – 1‑1.5 g twice daily; useful for patients intolerant to azathioprine.
• Rituximab – 1 g every 6 months for 2‑5 years, especially in patients with relapsing disease.
• Low‑dose glucocorticoids – Tapered gradually to ≤5 mg/day after remission.

Adjunctive & Supportive Care

• Trimethoprim‑sulfamethoxazole (TMP‑SMX) – 800/160 mg three times weekly for 12 months reduces relapse risk, especially in PR3‑ANCA positive patients.
• Proton‑pump inhibitor – Gastric protection while on steroids.
• Bone health – Calcium, vitamin D, and bisphosphonates if long‑term steroids used.
• Vaccinations – Inactivated vaccines (influenza, COVID‑19, pneumococcal) are recommended; avoid live vaccines while immunosuppressed.

Lifestyle Modifications

• Smoking cessation – reduces respiratory complications.
• Regular gentle exercise – improves stamina and bone health.
• Balanced diet rich in fruits, vegetables, and lean protein – helps counter steroid‑induced weight gain.

Living with Wegener’s Disease

Managing GPA is a lifelong partnership between the patient, rheumatologist, pulmonologist, nephrologist, and primary care provider.

Practical Daily Tips

• Medication adherence – Use a pill organizer or smartphone reminders; never stop steroids abruptly.
• Monitor signs of relapse – Keep a symptom diary (fever, new sinus pain, blood in urine, cough, or shortness of breath) and report changes promptly.
• Regular labs – CBC, renal panel, and ANCA titers are typically checked every 1‑3 months during induction, then every 3‑6 months.
• Skin care – Gentle cleansing; moisturize to prevent steroid‑related dryness.
• Infection precautions – Hand hygiene, avoid crowded sick contacts, and promptly treat any respiratory infections.
• Psychosocial support – Counseling, support groups (e.g., Vasculitis Foundation), and mental‑health resources can mitigate anxiety and depression common in chronic illness.
• Work and insurance – Discuss accommodations if fatigue or frequent medical visits interfere with work; many insurers cover disease‑modifying agents.

Prevention

Because the precise cause is unknown, primary prevention is limited. However, risk reduction strategies include:

• Avoiding occupational silica exposure – use protective masks and proper ventilation.
• Prompt treatment of chronic sinus infections – may reduce chronic antigenic stimulation.
• Screening for nasal carriage of Staphylococcus aureus and decolonizing with mupirocin if positive (studies suggest lower relapse rates).<sup>[7] Clin Infect Dis</sup>
• Staying up‑to‑date on vaccinations to reduce infection‑triggered flares.

Complications

If left untreated or inadequately controlled, GPA can cause irreversible organ damage.

• Renal failure – Crescentic glomerulonephritis may progress to end‑stage kidney disease requiring dialysis or transplant.
• Severe pulmonary hemorrhage – life‑threatening bleeding into the lungs.
• Permanent sinus and nasal deformities – septal perforation, saddle‑nose deformity.
• Peripheral neuropathy – chronic pain or functional loss.
• Cardiovascular disease – accelerated atherosclerosis from chronic inflammation and steroid exposure.
• Infection – Immunosuppressive drugs increase risk of bacterial, viral, and fungal infections.
• Medication toxicity – Cyclophosphamide can cause bladder toxicity, infertility, and secondary malignancies; long‑term steroids cause osteoporosis, diabetes, cataracts, and hypertension.

When to Seek Emergency Care

---

References (selected):

1. Centers for Disease Control and Prevention. “Vasculitis Statistics.” 2023.
2. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” Updated 2024.
3. National Institutes of Health. “Genetic Associations in ANCA‑Associated Vasculitis.” Nat Genet. 2022.
4. American College of Rheumatology/European Alliance of Associations for Rheumatology. “2022 Classification Criteria for GPA.” Arthritis Rheumatol. 2022.
5. Stone JH et al. “Rituximab versus Cyclophosphamide for ANCA‑Associated Vasculitis.” NEJM. 2010.
6. Walsh M et al. “Plasma Exchange in Severe ANCA‑Associated Vasculitis (PEXIVAS).” JAMA. 2020.
7. Stegeman C et al. “Staphylococcus aureus Decolonization Reduces Relapse in GPA.” Clin Infect Dis. 2021.

```